PURPOSE: To investigate the plasma-concentration profile of lorazepam when administered by the intranasal and buccal routes to determine their utility for the treatment of prolonged seizures. METHODS: On two occasions separated by at least 7 days washout, 12 healthy adult male volunteers received 2 mg of lorazepam via the intranasal or buccal route. Blood samples were collected at time periods from 0 to 48 h, and pharmacokinetic parameters were determined. RESULTS:Lorazepam was well absorbed from both administration routes; however, there was a more pronounced lag phase with the buccal route and absorption was more rapid from the intranasal route. CONCLUSIONS:Intranasal lorazepam has more favourable pharmacokinetics than buccal lorazepam when considering the need for the rapid blood concentrations required for seizure termination. Further clinical evaluation of this route is required.
RCT Entities:
PURPOSE: To investigate the plasma-concentration profile of lorazepam when administered by the intranasal and buccal routes to determine their utility for the treatment of prolonged seizures. METHODS: On two occasions separated by at least 7 days washout, 12 healthy adult male volunteers received 2 mg of lorazepam via the intranasal or buccal route. Blood samples were collected at time periods from 0 to 48 h, and pharmacokinetic parameters were determined. RESULTS:Lorazepam was well absorbed from both administration routes; however, there was a more pronounced lag phase with the buccal route and absorption was more rapid from the intranasal route. CONCLUSIONS: Intranasal lorazepam has more favourable pharmacokinetics than buccal lorazepam when considering the need for the rapid blood concentrations required for seizure termination. Further clinical evaluation of this route is required.
Authors: P D Knoester; D M Jonker; R T M Van Der Hoeven; T A C Vermeij; P M Edelbroek; G J Brekelmans; G J de Haan Journal: Br J Clin Pharmacol Date: 2002-05 Impact factor: 4.335
Authors: Michael Chicella; Paul Jansen; Anitha Parthiban; Karen F Marlowe; F Aladar Bencsath; Kem P Krueger; Robert Boerth Journal: Crit Care Med Date: 2002-12 Impact factor: 7.598
Authors: John McIntyre; Sue Robertson; Elizabeth Norris; Richard Appleton; William P Whitehouse; Barbara Phillips; Tim Martland; Kathleen Berry; Jacqueline Collier; Stephanie Smith; Imti Choonara Journal: Lancet Date: 2005 Jul 16-22 Impact factor: 79.321
Authors: S Shinnar; D C Hesdorffer; D R Nordli; J M Pellock; C O'Dell; D V Lewis; L M Frank; S L Moshé; L G Epstein; A Marmarou; E Bagiella Journal: Neurology Date: 2008-06-04 Impact factor: 9.910
Authors: Jishnu K S Krishnan; Peethambaran Arun; Bhadra Chembukave; Abhilash P Appu; Nivetha Vijayakumar; John R Moffett; Narayanan Puthillathu; Aryan M A Namboodiri Journal: J Neurosci Methods Date: 2017-05-10 Impact factor: 2.390
Authors: Abhishek G Sathe; Ellen Underwood; Lisa D Coles; Jordan J Elm; Robert Silbergleit; James M Chamberlain; Jaideep Kapur; Hannah R Cock; Nathan B Fountain; Shlomo Shinnar; Daniel H Lowenstein; Eric S Rosenthal; Robin A Conwit; Thomas P Bleck; James C Cloyd Journal: Epilepsia Date: 2021-02-10 Impact factor: 5.864